medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2017, Number 3

<< Back Next >>

Alerg Asma Inmunol Pediatr 2017; 26 (3)

Training on the 1-2-3 dihydrorodamine technique in different hospitals from Mexico for the diagnosis of chronic granulomatos disease

Espinosa PS, Guzmán MMN, Venegas ME, Jiménez PN, Medina TEA, Segura MNH, Romero VR, Satines BT, Santiago MMG, Alcántara SA, Sánchez PC, Llamas GB, Mojica CC, Saracho WF, González DLM, Terrazas LJM, Ochoa PEB, Guevara ME, Hernández FG, Bravo CA, Ortiz LPC, Torres LC, Gómez HN, Madrigal BI, Téllez CM, Martín AF, Moran MAR, López LD, López VE, Sandoval CA, Nava EM, Espinosa RF, Blancas GL

Language: Spanish
References: 14
Page: 76-83
PDF size: 238.90 Kb.


ABSTRACT

Chronic granulomatous disease (CGD) is a primary immunodeficiency (PID) in which there is an inability of phagocytes to produce free radicals. There are several screening techniques, one of the most sensitive and specific, already described in the literature is the 1,2-dihydrorhodamine (DHR) technique. Prior to our study and to our knowledge this last technique was not performed as a screening test for CGD in Mexico. The objective of this work was to implement the DHR for the diagnosis of CGD in different hospitals in Mexico. Health professionals from different pediatric hospitals, who diagnose and treat primary immunodeficiencies in Mexico were invited to participate in DHR technique training, considering that they had the appropriate infrastructure. 28 professionals from eight hospitals were trained. Currently all training centers are processing samples from CGD possible cases with DHR. Three of the eight centers already have positive cases of CGD patients and female carriers. There are PID that are not yet detected even the clinical suspicion, because there is not access to diagnostic tests, despite having a competent hospital staff and equipment. Our work model is an example of how the diagnosis and treatment of PIDs can be improved.


REFERENCES

  1. Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME et al. Primary immunodeficiency diseases: an update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015; 35: 696-726.

  2. Roos D. Chronic granulomatous disease. Br Med Bull. 2016; 118: 50-63.

  3. Vignais PV. The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. Cell Mol Life Sci. 2002; 59: 1428-1459.

  4. Leon LXB GL. Características epidemiólogicas, tipo de herencia y manifestaciones infecciosas de pacientes con enfermedad granulomatosa crónica. Tesis (especialidad en pediatría) UNAM Facultad de Medicina. 2017;tesis.unam.mx.

  5. Kim HY, Kim HJ, Ki CS, Kim DW, Yoo KH, Kang ES. Rapid determination of chimerism status using dihydrorhodamine assay in a patient with X-linked chronic granulomatous disease following hematopoietic stem cell transplantation. Ann Lab Med. 2013; 33: 288-292.

  6. Qin Y, Lu M, Gong X. Dihydrorhodamine 123 is superior to 2,7-dichlorodihydrofluorescein diacetate and dihydrorhodamine 6G in detecting intracellular hydrogen peroxide in tumor cells. Cell Biol Int. 2008; 32: 224-228.

  7. Roos D, de Boer M. Molecular diagnosis of chronic granulomatous disease. Clin Exp Immunol. 2014; 175: 139-49.

  8. Lun A, Schmitt M, Renz H. Phagocytosis and oxidative burst: reference values for flow cytometric assays independent of age. Clin Chem. 2000; 46: 1836-1839.

  9. Walrand S, Valeix S, Rodriguez C, Ligot P, Chassagne J, Vasson MP. Flow cytometry study of polymorphonuclear neutrophil oxidative burst: a comparison of three fluorescent probes. Clin Chim Acta. 2003; 331: 103-110.

  10. Cambray-Gutiérrez JC, Herrera-Sánchez DA, Blancas-Galicia L, O’Farrill-Romanillos PM. Clinic of humoral primary immunodeficiencies in adults. Experience in a tertiary hospital. Rev Alerg Mex. 2016; 63: 334-341.

  11. Staines BT. Descripción del cuadro clínico y defecto molecular de pacientes con enfermedad granulomatosa crónica en el Instituto Nacional de Pediatría. Tesis (especialidad en alergia e inmunología clínica pediátrica) UNAM Facultad de Medicina. 2005; tesis.unam.mx.

  12. Berron-Ruiz L, Morin-Contreras A, Cano-García V, Yamazaki-Nakashimada MA, Gómez-Tello H, Vargas-Camaño ME et al. Detection of inheritance pattern in thirty-three Mexican males with chronic granulomatous disease through 123 dihydrorhodamine assay. Allergol Immunopathol (Madr). 2014; 42: 580-585.

  13. Yamada M, Okura Y, Suzuki Y, Fukumura S, Miyazaki T, Ikeda H et al. Somatic mosaicism in two unrelated patients with X-linked chronic granulomatous disease characterized by the presence of a small population of normal cells. Gene. 2012; 497: 110-115.

  14. Marciano BE, Zerbe CS, Falcone EL, Ding L, DeRavin SS, Daub J et al. X-linked carriers of chronic granulomatous disease: illness, lyonization and stability. J Allergy Clin Immunol. 2017; pii: S0091-6749(17)30763-7.




2020     |     www.medigraphic.com